

in which

- R_1 , R_2 , R_3 , and R_4 are independently of each other, H, OH, a C_1 - C_4 alkoxy group, or an -OCOR₇ group, R_7 being a C_1 - C_4 alkyl group, at least one of the substituents R_1 , R_2 , R_3 , and R_4 being other than H and it being possible for R_2 and R_3 to form together a methylenedioxy group;

- R_5 is H, OH, a C_1 - C_4 alkoxy group, an O-glycosyl group, or a cyclohexyl group;

R_6 is a cyclohexyl group, a phenyl group, or a phenyl group substituted 1 to 3 times with H, OH, or a C_1 - C_4 alkoxy group;

- and ----- denotes either a double bond, or a single bond.

REMARKS

Applicant wishes to thank the examiner for acknowledging in the Office Action the claim to foreign priority under 35 USC 119 and receipt of the certified copy of the priority document, as requested.

Claims 16 and 18-24 are pending.

By the instant amendment claim 16 is amended. As amended hereby, method-of-treatment claim 16 involves administering "a cytotoxic potentiating amount of an isoflavonoid," instead of "a therapeutically effective" amount of the isoflavonoid. As such, what was implicit in claim 16 as originally submitted is, now, expressly recited in claim 16 as amended.